Immunoprecise Antibodies Debt 2024

Immunoprecise Antibodies Aktienanalyse

What does Immunoprecise Antibodies do?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Immunoprecise Antibodies's Debt Structure

Immunoprecise Antibodies's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Immunoprecise Antibodies's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Immunoprecise Antibodies’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Immunoprecise Antibodies’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Immunoprecise Antibodies stock

What is the debt of Immunoprecise Antibodies this year?

Immunoprecise Antibodies has a debt level of -1.01 CAD this year.

What was the debt of Immunoprecise Antibodies compared to the previous year?

The debt of Immunoprecise Antibodies has increased by -96.28% compared to the previous year dropped.

What are the consequences of high debt for investors in Immunoprecise Antibodies?

High debt can pose a risk for investors of Immunoprecise Antibodies, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Immunoprecise Antibodies?

Low debt means that Immunoprecise Antibodies has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Immunoprecise Antibodies affect the company?

An increase in debt of Immunoprecise Antibodies can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Immunoprecise Antibodies affect the company?

A reduction in debt of Immunoprecise Antibodies can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Immunoprecise Antibodies?

Some factors that can influence the debt of Immunoprecise Antibodies include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Immunoprecise Antibodies so important for investors?

The debts of Immunoprecise Antibodies are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Immunoprecise Antibodies take to change the debt?

To change the debt, Immunoprecise Antibodies can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Immunoprecise Antibodies pay?

Over the past 12 months, Immunoprecise Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunoprecise Antibodies is expected to pay a dividend of 0 CAD.

What is the dividend yield of Immunoprecise Antibodies?

The current dividend yield of Immunoprecise Antibodies is .

When does Immunoprecise Antibodies pay dividends?

Immunoprecise Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunoprecise Antibodies?

Immunoprecise Antibodies paid dividends every year for the past 0 years.

What is the dividend of Immunoprecise Antibodies?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunoprecise Antibodies located?

Immunoprecise Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunoprecise Antibodies from 9/27/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Immunoprecise Antibodies pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Immunoprecise Antibodies in the year 2023?

In the year 2023, Immunoprecise Antibodies distributed 0 CAD as dividends.

In which currency does Immunoprecise Antibodies pay out the dividend?

The dividends of Immunoprecise Antibodies are distributed in CAD.